The Choroid Plexus and Cerebrospinal Fluid: Emerging Roles in Development, Disease, and Therapy

Maria K. Lehtinen, Christopher S. Bjornsson, Susan M. Dymecki, Richard J. Gilbertson, David M. Holtzman, and Edwin S. Monuki

Department of Pathology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts 02115; Neural Stem Cell Institute, Rensselaer, New York 12144; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115; St. Jude Children’s Research Hospital, Memphis, Tennessee 38105; Department of Neurology, Washington University, St. Louis, Missouri 63110; and Department of Pathology and Laboratory Medicine, University of California, Irvine School of Medicine, Irvine, California 92697

Although universally recognized as the source of cerebrospinal fluid (CSF), the choroid plexus (ChP) has been one of the most understudied tissues in neuroscience. The reasons for this are multiple and varied, including historical perceptions about passive and permissive roles for the ChP, experimental issues, and lack of clinical salience. However, recent work on the ChP and instructive signals in the CSF have sparked new hypotheses about how the ChP and CSF provide unexpected means for regulating nervous system structure and function in health and disease, as well as new ChP-based therapeutic approaches using pluripotent stem cell technology. This minisymposium combines new and established investigators to capture some of the newfound excitement surrounding the ChP-CSF system.

Introduction

Almost 100 years ago to date, Harvey Cushing made the seminal discovery that the choroid plexus (ChP), a highly vascularized tissue located in each ventricle of the brain, secretes cerebrospinal fluid (CSF) (Cushing, 1914), casting aside lingering views of the CSF as a possible postmortem precipitate. In humans, the ChP produces 400 – 600 ml of CSF each day, which is enough to turn over the CSF 4–5 times. The CSF then flows from the lateral ventricles to the third and fourth ventricles, and then into the subarachnoid space of the brain and spinal cord via openings (foramina) below the cerebellum (Fig. 1). The CSF returns to the peripheral circulation via resorption by arachnoid granulations in venous sinuses of the brain (Segal, 2005). The ChP-CSF system therefore represents an independent circulatory system for the brain and spinal cord.

The ChP-CSF system is also unique in terms of how understudied it has been. A reflection of this comes from last year’s Society for Neuroscience meeting: of the 17,255 searchable abstracts, only 9 had “choroid plexus” in the title or as a keyword. Why is that? Part of the answer may relate to the generally perceived “uninteresting” functions historically attributed to the CSF, such as providing buoyancy and acting as a passive sink for waste. The ChP has also had limited salience in the clinical arena. ChP pathology in most neurological or psychiatric conditions is nonspecific (atrophy or accelerated atrophy), and apart from uncommon types of hydrocephalus, the ChP is not known to be responsible for primary symptoms or particularly helpful for differential diagnosis. There have also been experimental barriers, including a relative lack of ChP-selective tools, difficulties obtaining CSF from small animal models, and challenges inherent in studying a fluid rather than a tissue.

Recent advances, however, have begun to transform our view of the ChP-CSF system. Newer techniques indicate that CSF is a rich source of proteins, lipids, hormones, cholesterol, glucose, microRNAs, and many other molecules and metabolites that influence a multitude of CNS functions, including neurogenesis in embryos and adults (Dziegielewski et al., 1981; Zappapetra et al., 2007; Lehtinen and Walsh, 2011; Zappapetra and Lehtinen, 2012; Burgos et al., 2013). Spurred by the clinical utility of CSF biomarkers for Alzheimer’s disease, there is tremendous interest in CSF biomarker discovery for the diagnosis and management of CNS disorders, and the ability to derive secretory ChP cells from embryonic stem cells sets the stage for unique ChP-based strategies for treating a host of CNS diseases. In this minireview, we highlight some of the new roles and emerging principles for the ChP-CSF system in the areas of development, disease, and therapy.

Choroid plexus development

Only recently have investigators begun to use modern techniques to study development of the ChP itself. The ChP forms at and...
adjacent to the embryonic dorsal midline in the hindbrain, diencephalon, and telencephalon. Whereas ChP stroma has mesenchymal origins, including meningeal cells, ChP epithelial cells (CPECs) are derived from neuroepithelium, and important aspects of CPEC specification are now understood. Genetic lineage analyses indicate that CPECs originate from the roof plate (Awatramani et al., 2003; Currie et al., 2005; Hunter and Dymecki, 2007), a well-known signaling center in early CNS development. Roof plate cells differentiate directly into CPECs at all four ChP sites, although in the telencephalon, most CPECs are induced indirectly by the roof plate (Bailey, 1915; Currie et al., 2005), and multiple studies implicate bone morphogenetic proteins as the instructive roof plate-derived molecules for CPEC fate (Hebert et al., 2002; Cheng et al., 2006; Fernandes et al., 2007; Watanabe et al., 2012). CPEC differentiation is evident before definitive neurogenesis or ependymal differentiation ensues, and in vivo and in vitro mouse studies indicate that CPEC competency is restricted to early-stage neuroepithelial cells in the telencephalon and roof plate regions (Thomas and Dziadek, 1993; Watanabe et al., 2012).

Other studies have begun to clarify the epithelial–mesenchymal interactions involved in ChP development. Recent genetic experiments in the mouse embryo (Huang et al., 2009; Nielsen and Dymecki, 2010) reveal a central role for the secreted morphogen Sonic Hedgehog (Shh) in coordinating the developmental challenge of matching CPEC numbers to vasculature. The critical source of Shh was found to be embryonic CPECs (Bitgood and McMahon, 1995; Huang et al., 2009; Nielsen and Dymecki, 2010) (Fig. 2). The responding cell populations were found to be the perivascular cells (pericytes) in the underlying ChP vascular bed (Nielsen and Dymecki, 2010), and the progenitor cells for the ChP located laterally (Huang et al., 2009). CPECs are postmitotic, expanding through cell addition supplied by progenitor cells residing in the lateral periphery of the hindbrain ChP, in a territory situated in neuroectoderm and demarcated molecularly by expression of the transcription factor Lmx1a and the secreted signaling molecule Gdf7 (Currie et al., 2005; Landsberg et al., 2005; Hunter and Dymecki, 2007; Chizhikov et al., 2010). Thus, although Shh is present in CSF, here it acts on cell populations constituent to, even internal to, the ChP, suggesting Shh release across the basal surface of the epithelium to deeper mesenchymal cells like pericytes, as opposed to only apical release into the CSF.

Shh, acting on these two cell populations (pericytes and CPEC progenitor cells), was found to regulate at least two key processes: outgrowth of vasculature in the ChP and enhanced CPEC generation from their neuroectodermal progenitor pool to ensheathe that expanding vasculature. In the absence of CPEC-produced Shh, a severely hypoplastic structure develops, deficient in CPEC and vasculature, as well as showing reduced folding of the ChP surface (Huang et al., 2009; Nielsen and Dymecki, 2010). Shh thus appears to orchestrate the codevelopment of two disparate cell lineages during ChP morphogenesis: underlying perivascular cells and more distant CPEC progenitor cells. The relative contribution of each of these Hh-responsive populations to overall ChP development remains to be delineated and is an area of active investigation. For example, it seems straightforward that pericyte action in response to Shh likely enables vascular expansion and outgrowth, but pericytes may also serve, via factor secretion, to boost CPEC production from the neuroectodermal progenitor pool. Answers to these possibilities await additional manipulations of Shh pathway genes, restricted to pericytes versus CPEC progenitors.

**CSF and distribution of instructive cues in development**

Beyond development of the ChP itself, recent studies have begun to delineate how the embryonic ChP regulates development of the rest of the brain. The earliest born neural stem cells in the developing cerebral cortex are located along CSF-filled ventricles (Fig. 3A). A number of genes that directly regulate cortical progenitor cell proliferation and migration have been identified, and most of these genes are expressed by cortical progenitor cells (Thornton and Woods, 2009; Manzini and Walsh, 2011). The large literature on brain development also demonstrates critical roles that extrinsic cues, including growth factors and morphogens (e.g., Fgf, Bmps, Shh, Wnt, and RA), have on cortical progenitor cells (for review, see Lehtinen and Walsh, 2011; Tiberi et al., 2012). Yet the evidence from the majority of these studies has never fully explained how these signals access cortical progenitors at the ventricular surface, where the primary access to signals is likely via the CSF. Recent studies have begun to probe this question and, indeed, have demonstrated that secreted signals emanating from the CSF provide growth-promoting signals to neural stem cells (Lehtinen et al., 2011).

Embryonic CSF, without any additional exogenous growth-promoting signals, can promote the development and growth of neural stem cells and cortical explants, and the favorable effects of CSF are age-dependent (Lehtinen et al., 2011). For example, young stem cells bathed in embryonic CSF divide robustly. By contrast, the same stem cells bathed in CSF obtained at other ages, including adult CSF, display only limited cell division. These results agree with findings that many protein signals in the CSF fluctuate with age. For instance, CSF-insulin-like growth factor-2 (IGF2) levels, attributed largely to ChP secretion, peak during brain development. CSF-IGF2 stimulates cell division by binding to receptors on the surface of neural stem cells (Lehtinen et al., 2011). Intracerebroventricular injections of IGF1, IGF1-neutralizing antibodies, and IGF1R inhibitors further demonstrate that IGF signals delivered by the embryonic CSF stimulate proliferative events in the cortical ventricular zone (Mairet-Coello et al., 2009). Finally, mouse genetic approaches have further shown that IGF2 regulates neurogenesis, formation of the uppermost layers of the cerebral cortex, and brain size (Lehtinen et al., 2011).

Intriguingly, when neural stem cells lose their distinct polarity, including genetic manipulation of the polarity gene Pals1...
Overview of ChP-CSF–brain interactions. In addition to secreting CSF, ChP epithelial cells secrete morphogens and proteins with sites of action within the ChP (e.g., Shh on vasculature and ChP progenitor cells) and beyond the ChP on neural stem cells (e.g., IGF2 on cerebral cortical progenitor cells, and cytokines on adult neural stem cells). The ChP can be the site of tumorigenesis (brown). It also plays a role in protecting the brain from Aβ toxicity. Because there is an exchange between the brain’s interstitial fluid and CSF (perforated line), the ratio of phosphorylated Tau:Aβ provides an early diagnostic for Alzheimer’s disease and can predict the severity of neurodegenerative decline. Recent advances have made possible the engineering and production of ES-derived ChP epithelial cells (green).

Figure 2.
Choroid plexus tumors

As with virtually all tissues of the body, the ChP can be a target for cancer as well. CPECs are the presumed cells of origin for most ChP tumors, although rare intraventricular meningiomas are thought to arise from neoplastic meningeal cells in ChP stroma. Although tumors of the ChP are rare in children and adults, accounting for <2% of all pediatric brain tumors (CBTRUS, 2006; Paulus and Brandner, 2007), they are most commonly observed in infants (accounting for 10–20% of brain tumors in infants in their first year; median age of diagnosis, 3.5 years) (Safaee et al., 2013) (Fig. 2). Efforts to assemble the critical mass of patients and experts necessary to advance cures of the disease have proved relatively unsuccessful, and treatment options and survival rates remain limited (Wolff et al., 2002; Lafay-Cousin and Strother, 2009). Recent developments have innovated a cross-species genomics approach that allows mapping of the cells of origin of childhood brain tumors. Targeting these cells in mice with appropriate mutations identified in the human disease results in brain tumor models that recapitulate human tumors (Gibson et al., 2010; Johnson et al., 2010; Gilbertson, 2011). This approach allows for the application of these model systems in high-throughput drug screens of new treatments that can be rapidly translated to the clinic (Atkinson et al., 2011).

The R.J.G. laboratory has adapted this same approach to increase understanding of the biology and treatment of pediatric choroid plexus carcinoma (CPC). In a collaboration involving experts in brain tumor biology, neurobiology, genomics, neuro-pathology, and drug development, they have used in vitro electroporation to develop a new and highly flexible model of CPC. Comprehensive histologic and genomic analyses of these tumors have validated these mouse tumors as faithful models of human CPC and enabled the identification of nonrandom large chromosomal and focal alterations that are secondary events in the development of CPCs. Further in vitro electroporation studies of these aberrantly altered genes have identified those that alter normal ChP development and might therefore impact CPC formation. Finally, cells from this CPC model have been adapted for high-throughput drug screens. To date, mouse models have been screened against >1.2 million compounds, identifying numerous highly active novel agents for further preclinical testing, which we hope will improve the survival of children with CPC.

CSF in Alzheimer’s disease

Recent studies suggest that the ChP-CSF system plays central roles in Alzheimer’s disease (AD), the most common cause of dementia. It is estimated that there are ~30 million cases of AD worldwide, and this number will triple in the next 40 years unless a disease-modifying therapy is developed (Holtzman et al., 2011). An important series of findings over the last 25 years in both the rare forms of early-onset, dominantly inherited AD (<1% of AD) as well as in the common late-onset AD (age of onset >60, >99% of AD) is that the pathology underlying the disease begins to develop ~15 years before the onset of cognitive decline. By the time that cognitive decline is present, there is not only substantial amyloid-β (Aβ) deposition in the form of amyloid plaques, there is also tau aggregation in the form of neurofibrillary tangles, neuroinflammation, and neuronal and synaptic loss in certain brain regions (Fagan et al., 2009; Perrin et al., 2009). Thus, although our understanding of the pathogenesis of AD has greatly increased, if we are to develop effective treatments that can delay the onset or slow AD, it will be critical to accurately diagnose...
AD both in its early clinical stages as well as before the onset of cognitive decline (preclinical AD).

Dynamic and static assessments of several CSF proteins have proven to be very useful in detecting different aspects of AD pathology as well as in identifying fundamental aspects of protein metabolism relevant to AD. CSF levels of Aβ42 decrease with the onset of Aβ deposition in the brain beginning ∼10–15 years before the onset of cognitive decline. This is the result of an equilibrium between soluble monomeric Aβ42 in CSF, brain interstitial fluid, and amyloid plaques (Fig. 2). CSF tau and phosphorylated forms of tau increase in CSF ∼5–10 years before cognitive decline, probably because of an increase in tau release from neurons related in some way to neurodegeneration. The combination of these changes can predict the rate of decline in individuals who have mild cognitive impairment/very mild dementia resulting from AD, as well as the conversion from cognitive normality to dementia over a 5-year period. In addition to tau, another marker of neurodegeneration in CSF is the neuronal protein Vilip-1 (Tarawneh et al., 2011), which has similar diagnostic and prognostic value to tau in AD. In addition to static measurement of these proteins in CSF, using metabolic labeling with 13C-labeled amino acids, the synthesis and clearance rate of Aβ are extremely rapid in the CNS/CSF (on the order of hours) (Bateman et al., 2006). Interestingly, the clearance rate of Aβ appears to be slower in individuals with AD compared with age-matched controls, suggesting that slowed Aβ clearance may be central in causing late-onset AD. In dominantly inherited early-onset AD, the production rate of Aβ42 relative to Aβ40 is elevated in many individuals as predicted (Potter et al., 2013). However, the turnover rate of CSF Aβ42 is faster in these individuals if they already have amyloid plaques, suggesting active deposition of soluble Aβ42 into plaques. Together, these findings suggest that the kinetics of biomarker availability in the CSF serve as a harbinger of cognitive fitness, opening avenues toward the possibility of harnessing the CSF for tailoring personalized therapeutic approaches for detecting, diagnosing, and treating AD in the aging brain.

**Choroid plexus in therapy**

Despite the many recent advances in medicine, effective therapies for most CNS diseases remain few and far between. The reasons for this are many but include the complexities of the human CNS itself and the many difficulties in getting therapeutic compounds past CNS barriers, particularly the blood-brain barrier (BBB). Because there is no CSF–brain barrier (Goldmann, 1913), CNS delivery past these barriers can be achieved clinically by direct injections into the CSF (intrathecal or intraventricular) (e.g., Dickson et al., 2007). However, such injections come with multiple downsides, such as the many repeated treatments needed over a lifetime and associated safety issues. Cell-based therapies that are long-lived, safe, and provide long-term delivery to the CSF would circumvent these issues and could represent ideal therapeutic strategies for treating many CNS diseases. The promise of CPA-based therapies has been shown using transplanted primary choroid plexus (e.g., encapsulated porcine ChP) (Thanos et al., 2010) and CPA-tropic AAV viruses (Haskell et al., 2003), although these approaches also have inherent limitations (e.g., Manno et al., 2006).

A stem cell-based approach for generating CPECs (patent pending) (Watanabe et al., 2012) that could address many of these limitations was recently described. CPECs are the workhorse cells that perform the major secretory, transport, detoxification, and barrier functions of the ChP. CPECs are born to secrete CSF, normally producing 400–600 ml (approximately 2 cups) of CSF every day in humans, which is continuous with brain interstitial fluid across ependymal, pial, and certain peripheral surfaces (Serot et al., 2000; Emerich et al., 2005) (Fig. 2). *In vivo*, CPECs are long-lived, exhibiting little proliferation or turnover; accordingly, primary CPECs have been difficult to expand in culture to a significant degree (Watanabe et al., 2012). Using ES cells as starting material (which circumvents the expandability problem), the production of derived CPECs (dCPECs) follows important developmental principles, such as the ability of BMP4 to act as an instructive morphogen for CPEC fate (Cheng et al., 2006; Hu et al., 2008) and the restriction of CPEC potential to early-stage neuroepithelial cells rather than later-stage radial glia (Thomas and Dziadek, 1993). Importantly, both primary and dCPECs can integrate readily into host ChP after intraventricular injection (Watanabe et al., 2012), which represents an attractive and clinically feasible approach for dCPEC-based therapies (Fig. 2). Given that multiple highly expressed CPEC gene loci have been identified (e.g., the *TRANSFHYRETIN* gene), genetic engineering approaches to produce high levels of therapeutic proteins or peptides for natural, safe, and long-term delivery into the CNS should now be feasible. The ability to generate and engineer dCPECs could represent transformative approaches for treating a wide range of CNS diseases. In addition, given the lack of significant barriers between the bloodstream and the ChP itself, dCPECs provide a new, clinically feasible target for drug screens and therapeutic strategies that can bypass the BBB (Gonzalez et al., 2012).

In conclusion, the ChP-CSF system actively coordinates the development and health of the nervous system throughout life. The growing body of work on the ChP-CSF system summarized in this minireview marks the beginning of a new era for studies of this system. Understanding the constituency of the CSF and the actions of the ChP-CSF system is important not only for guiding basic biology and stem cell research but also for propelling current and potential uses in pharmacologic and surgical therapies for hydrocephalus, cancer, neurodegenerative disease, and beyond. Because the ChP-CSF system interacts with essentially every other system in the CNS, we hope this “state of the field address” provides inspiration for advancing past outdated conceptual and technical barriers in the field, sparking initiatives that will harness what the ChP-CSF system has to offer in service of nervous system repair.

---

**References**


---

**Choroid Plexus and Cerebrospinal Fluid** J. Neurosci., November 6, 2013 • 33(45):17553–17559 • 17557


Mairet-Coello G, Tury A, DiCicco-Bloom E (2009) Insulin-like growth factor-1 promotes G1/S cell cycle progression through bidirectional regulation of cyclins and cyclin-dependent kinase inhibitors via the phos-
phatidylinositol 3-kinase/Akt pathway in developing rat cerebral cortex. J Neurosci 29:775–788. CrossRef Medline